KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Assets: 2009-2024

Historic Current Assets for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $938.3 million.

  • Acadia Pharmaceuticals' Current Assets rose 36.55% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 36.55%. This contributed to the annual value of $938.3 million for FY2024, which is 52.29% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Current Assets stood at $938.3 million for FY2024, which was up 52.29% from $616.1 million recorded in FY2023.
  • Acadia Pharmaceuticals' Current Assets' 5-year high stood at $938.3 million during FY2024, with a 5-year trough of $507.9 million in FY2022.
  • Over the past 3 years, Acadia Pharmaceuticals' median Current Assets value was $616.1 million (recorded in 2023), while the average stood at $687.5 million.
  • Its Current Assets has fluctuated over the past 5 years, first dropped by 17.79% in 2022, then surged by 52.29% in 2024.
  • Acadia Pharmaceuticals' Current Assets (Yearly) stood at $717.6 million in 2020, then decreased by 13.91% to $617.8 million in 2021, then decreased by 17.79% to $507.9 million in 2022, then increased by 21.30% to $616.1 million in 2023, then soared by 52.29% to $938.3 million in 2024.